BioCentury | Oct 13, 2020
Product Development

Data Bytes: coronavirus-targeted small molecules

...preclinical development: Anivive Lifesciences Inc., Cocrystal Pharma Inc. (NASDAQ:COCP), Insilico Medicine Inc., Pardes Biosciences Inc. and Sosei Group Corp....
BioCentury | Oct 1, 2020
Management Tracks

CVS’s Asgarian joins Thrive as CMO; plus Black Diamond names Ingram chairman and updates from MorphoSys, G1 and more

...Bains as chief business officer. Bains was previously CEO of Sosei Heptares, a unit of Sosei Group Corp....
BioCentury | Sep 10, 2020
Finance

MiNA raises £23M in first venture round 12 years after launch

...By Virginia Li, Associate Editor After financing itself for 12 years via high-net-worth individuals and Sosei...
...from high-net worth individuals and through a £35 million investment from Sosei Group Corp. (Tokyo:4565) in 2017 (see “RNA is for Activation”; “Sosei...
BioCentury | Sep 8, 2020
Management Tracks

Black Diamond names Humphrey CMO; plus Edmondson to lead chemistry at Nimbus, Recce, Amarna and more

...Cahlen as CEO, effective Nov. 1, to succeed Mats Grahn, who now sits on the board.Sosei Group Corp....
BioCentury | Jun 30, 2020
Regulation

Data Bytes: Drug approvals in Japan

...plc Novo Nordisk A/S Mitsubishi Tanabe Pharma Corp. Akebia Therapeutics Inc. Kyowa Kirin Co. Ltd. Chugai Pharmaceutical Co. Ltd. Novartis AG Incyte Corp. Sosei Group Corp....
BioCentury | Jun 26, 2020
Deals

Sosei Heptares gains new GPCR discovery partner in AbbVie

...four targets, will pay Sosei up to $32 million in upfront and near-term milestone payments. Sosei...
...and near-term payments in exchange for exclusive, global rights to candidates from Sosei’s StaR platform. Sosei...
...with Sosei Heptares” ). The AbbVie collaboration will initially focus on inflammatory and autoimmune diseases. Sosei’s...
BioCentury | Apr 15, 2020
Product Development

AZ targeting cytokine storms as ranks of repurposed agents for COVID-19 grow

...development for COVID-19, according to BioCentury’s COVID-19 Resource Center . Sosei searching for protease inhibitors Sosei Group Corp....
...Tumor necrosis factor alpha Elizabeth S. Eaton, Staff Writer Calquence (Brand), ACP-196 (Compound #), acalabrutinib (Generic) AstraZeneca plc Sosei Group Corp. Sinovac...
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

...rather than an inflammatory and fibrotic condition (see “Standing Out in the NASH Crowd” ). Sosei Group Corp....
...CEO of Clinical Innovations LLC. Robin Sawka, BioCentury Staff Qiagen N.V. CytomX Therapeutics Inc. Recursion Pharmaceuticals Inc. 89bio Inc. Heptares Therapeutics Ltd. Sosei Group Corp. Fusion...
BioCentury | Jan 25, 2020
Product Development

A milestone year for Roche’s CNS gambit could kick off its plan for the decade

...“Roche’s CNS Deals”). While four were with established public biotechs -- Ionis Pharmaceuticals Inc. (NASDAQ:IONS), Sosei Group Corp....
BioCentury | Jan 15, 2020
Financial News

Jan. 14 Financial Quick Takes: Schrödinger proposes NASDAQ IPO; plus Mirati, Blackstone, Orexia, Jasper, seqWell

...which plans to invest up to a total of €40 million ($44.5 million) in the Sosei Group Corp....
Items per page:
1 - 10 of 421
BioCentury | Oct 13, 2020
Product Development

Data Bytes: coronavirus-targeted small molecules

...preclinical development: Anivive Lifesciences Inc., Cocrystal Pharma Inc. (NASDAQ:COCP), Insilico Medicine Inc., Pardes Biosciences Inc. and Sosei Group Corp....
BioCentury | Oct 1, 2020
Management Tracks

CVS’s Asgarian joins Thrive as CMO; plus Black Diamond names Ingram chairman and updates from MorphoSys, G1 and more

...Bains as chief business officer. Bains was previously CEO of Sosei Heptares, a unit of Sosei Group Corp....
BioCentury | Sep 10, 2020
Finance

MiNA raises £23M in first venture round 12 years after launch

...By Virginia Li, Associate Editor After financing itself for 12 years via high-net-worth individuals and Sosei...
...from high-net worth individuals and through a £35 million investment from Sosei Group Corp. (Tokyo:4565) in 2017 (see “RNA is for Activation”; “Sosei...
BioCentury | Sep 8, 2020
Management Tracks

Black Diamond names Humphrey CMO; plus Edmondson to lead chemistry at Nimbus, Recce, Amarna and more

...Cahlen as CEO, effective Nov. 1, to succeed Mats Grahn, who now sits on the board.Sosei Group Corp....
BioCentury | Jun 30, 2020
Regulation

Data Bytes: Drug approvals in Japan

...plc Novo Nordisk A/S Mitsubishi Tanabe Pharma Corp. Akebia Therapeutics Inc. Kyowa Kirin Co. Ltd. Chugai Pharmaceutical Co. Ltd. Novartis AG Incyte Corp. Sosei Group Corp....
BioCentury | Jun 26, 2020
Deals

Sosei Heptares gains new GPCR discovery partner in AbbVie

...four targets, will pay Sosei up to $32 million in upfront and near-term milestone payments. Sosei...
...and near-term payments in exchange for exclusive, global rights to candidates from Sosei’s StaR platform. Sosei...
...with Sosei Heptares” ). The AbbVie collaboration will initially focus on inflammatory and autoimmune diseases. Sosei’s...
BioCentury | Apr 15, 2020
Product Development

AZ targeting cytokine storms as ranks of repurposed agents for COVID-19 grow

...development for COVID-19, according to BioCentury’s COVID-19 Resource Center . Sosei searching for protease inhibitors Sosei Group Corp....
...Tumor necrosis factor alpha Elizabeth S. Eaton, Staff Writer Calquence (Brand), ACP-196 (Compound #), acalabrutinib (Generic) AstraZeneca plc Sosei Group Corp. Sinovac...
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

...rather than an inflammatory and fibrotic condition (see “Standing Out in the NASH Crowd” ). Sosei Group Corp....
...CEO of Clinical Innovations LLC. Robin Sawka, BioCentury Staff Qiagen N.V. CytomX Therapeutics Inc. Recursion Pharmaceuticals Inc. 89bio Inc. Heptares Therapeutics Ltd. Sosei Group Corp. Fusion...
BioCentury | Jan 25, 2020
Product Development

A milestone year for Roche’s CNS gambit could kick off its plan for the decade

...“Roche’s CNS Deals”). While four were with established public biotechs -- Ionis Pharmaceuticals Inc. (NASDAQ:IONS), Sosei Group Corp....
BioCentury | Jan 15, 2020
Financial News

Jan. 14 Financial Quick Takes: Schrödinger proposes NASDAQ IPO; plus Mirati, Blackstone, Orexia, Jasper, seqWell

...which plans to invest up to a total of €40 million ($44.5 million) in the Sosei Group Corp....
Items per page:
1 - 10 of 421